Skip to main content

Table 3 3-O-methyl glucose absorption: post-dose vs. baseline comparison (excluding the n = 2 without adequate camicinal exposures)

From: The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial

Plasma 3-OMG

Comparison

Baseline

Post study drug

Point estimate

95 % CI

(mean)

(mean)

AUC(0–240) (mmol.min/L)*

50 mg (n = 15)

28.630

71.632

2.502

(1.683, 3.719)

50 mg (n = 13)#

33.042

74.587

2.257

(1.478, 3.449)

75 mg (n = 6)

48.373

35.048

0.725

(0.387, 1.356)

Placebo (n = 12)

45.791

60.699

1.326

(0.851, 2.065)

AUC(0–60) (mmol.min/L)*

50 mg (n = 15)

2.962

11.646

3.932

(2.037, 7.588)

50 mg (n = 13)#

3.779

12.390

3.279

(1.631, 6.592)

75 mg (n = 6)

9.698

4.914

0.507

(0.179, 1.433)

Placebo (n = 12)

5.935

7.464

1.258

(0.603, 2.623)

Cmax (mmol/L)*

50 mg (n = 15)

0.1905

0.4287

2.2505

(1.5736, 3.2186)

50 mg (n = 13)#

0.2107

0.4496

2.1344

(1.4389, 3.1662)

75 mg (n = 6)

0.3530

0.2512

0.7116

(0.4042, 1.2530)

Placebo (n = 12)

0.3035

0.3824

1.2600

(0.8446, 1.8797)

  1. 3-OMG 3-O-methyl glucose, CI confidence interval, AUC area under the curve, Cmax peak 3-OMG concentration
  2. *Log-transformed
  3. #Two subjects administered 50 mg camicinal had low drug exposure. Analyses were performed with and without these subjects
Back to article page

Critical Care

ISSN: 1364-8535